Tag Archives: transparency

Want Quality Care for Wet Macular Degeneration:
Patients Know Little About MD Biases, Experience

Posted on May 22, 2012 by Laura Newman

Just about a year ago, I reported the one-year results for the Comparison of AMD Treatments Trial (CATT), which compared Lucentis, the high-cost injectable medication made by Genentech with Avastin, also made by Genentech. A lot has happened in the … Continue reading →

Posted in comparative effectiveness research, Physician bias | Tagged , , , , , | 4 Comments

On Disclosure, Transparency, and Firewalls: A Call for Uniform Standards

Posted on May 7, 2011 by Laura Newman

Since Patient POV was launched March 29, I have been struggling with how to deal with the issue of industry-supported patient advocacy groups. On Thursday, ProPublica released its paper: “Financial Ties Bind Medical Societies to Drug and Device Makers” with … Continue reading →

Posted in American Academy of Ophthalmology, Avastin, disclosure, Drug costs, firewalls, nonprofits, Parkinson's Disease Foundation, patient advocacy groups, transparency | Tagged , , , , | 9 Comments